Eli Lilly reported its financial results for the full year ended December 31, 2025, with revenue reaching USD 65.18 billion, up 45 percent. Net income for the period was USD 20.64 billion, an increase of nearly double the previous year. Diluted earnings per share stood at USD 22.95, rising 96 percent. The growth in revenue was primarily driven by increased volume, particularly from the products Mounjaro and Zepbound, partially offset by lower realized prices. The rise in net income and earnings per share was mainly attributed to higher gross margin, despite increased marketing, selling, and administrative expenses as well as higher research and development spending. Eli Lilly stated that its available cash and cash equivalents, along with its ability to generate operating cash flow and access to borrowings, are sufficient to fund its planned capital requirements, including working capital, capital expenditures, shareholder returns, debt repayment, milestone and royalty payments, and potential business development activities such as acquisitions and licensing arrangements. The company also highlighted continued advancement in its clinical development pipeline, with select new molecular entities and new indication line extension products currently in clinical trials, under regulatory review, or recently receiving regulatory approval in major markets including the U.S., EU, and Japan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000059478-26-000013), on February 12, 2026, and is solely responsible for the information contained therein.